Belzutifan Drug Asset Due Diligence Report 2026

This Belzutifan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Belzutifan can convert its Small molecule drug profile and HIF-2α biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Belzutifan (query alias: belzutifan)
Modality / target	Small molecule drug; HIF-2α; HIF-2α inhibitors
Highest global status	Approved
Originator	Merck Sharp & Dohme Corp.
Active developers	Merck Sharp & Dohme Corp., Merck Sharp & Dohme LLC, MSD R&D (China) Co. Ltd.

The MCP disease footprint includes Metastatic Renal Cell Carcinoma, Paraganglioma, Pheochromocytoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07489495	Phase 3	Recruiting	758	Progression-free Survival (PFS)
NCT07593040	Phase 2	Not yet recruiting	150	Response Rate
NCT07700758	Phase 2	Not yet recruiting	15	Number of Participants Who Experience One or More Adverse Events (AEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 150 RCC patients.

Not Applicable; n=150; evaluation: Positive. Reported fields: ARID1A = 5.1 % ; ARID1A = 1.8 %

LITESPARK-033: Phase 3 study of belzutifan plus zanzalintinib versus cabozantinib for recurrent clear cell renal cell carcinoma during or after adjuvant anti–PD-(L)1 therapy.

Phase 3; n=904; evaluation: Positive. Reported fields: OS = NR ; OS = NR

Real-world overall survival outcomes of belzutifan treatment in advanced renal cell carcinoma.

Not Applicable; n=2844; evaluation: Positive. Reported fields: OS(12-month) = 68.1 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Belzutifan addresses Metastatic Renal Cell Carcinoma, Paraganglioma, Pheochromocytoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-10-14	Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma	Approved	Financial terms not disclosed
2019-05-21	Merck & Co., Inc. completed the acquisition of Peloton Therapeutics, Inc. from The Column Group LLC.	Phase 2	US$1,050.0M upfront; US$1,150.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treating cancer using combinations of GCN2 modulators and belzutifan”. The milestone feed surfaced a patent-application signal described as “A process for the preparation of belzutifan and its novel intermediates thereof”. The milestone feed surfaced a patent-application signal described as “Combination of Anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO